Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective
treatment for advanced non-small cell lung cancer. The objective of the present study was to …

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths. In
the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has …

PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …

INTRODUCTION: Some patients with advanced NSCLC show prolonged disease
stabilization on treatment with an EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib. It is …

Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …

Background Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …

Overexpression and mutational activation of the epidermal growth factor receptor (EGFR) is
involved in tumor development and progression in non-small-cell lung cancer (NSCLC) …

Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …

The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior
to chemotherapy as first-line therapy for advanced non-small cell lung cancers (NSCLC) that …